ClinicalTrials.gg
Active, not recruitingNCT05973773REZILIENT3Updated Nov 3, 2026

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

A Phase 3 interventional study of TAS6417 in Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation, sponsored by Taiho Oncology, Inc.. Active, not recruiting at 110 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Primary conditionCarcinoma, Non-Small-Cell LungRegistry: Lung DiseasesReclassifiedWhy we changed it
Registry
Lung Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Non-Small-Cell Lung
Why
  1. The study's title name Carcinoma, Non-Small-Cell Lung, a narrower term within Lung Diseases.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Taiho Oncology, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Updated Nov 3, 2026No longer in Bulgaria30 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
285
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Carcinoma, Non-Small-Cell Lung by Otsuka Holdings Co., Ltd. — 3 open to participants now, 4 under way, 2 of them phase 3. Carcinoma, Non-Small-Cell Lung · Otsuka Holdings Co., Ltd..

Enrollment
3rd of 11
285 · median 128
Started
2023
with 1 other
Phase 3
2 of 13
1 open now
Registered
11th of 13
by date

Among the 13 studies in Carcinoma, Non-Small-Cell Lung by Otsuka Holdings Co., Ltd., this one is the 3rd largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2023, is one of 2 in phase 3, and was the 11th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

3 of the 13 studies in Carcinoma, Non-Small-Cell Lung by Otsuka Holdings Co., Ltd. are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Carcinoma, Non-Small-Cell Lung by Otsuka Holdings Co., Ltd., or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of zipalertinib in combination with standard first-line platinum-based chemotherapy compared to chemotherapy alone, in patients with locally advanced or metastatic NSCLC with EGFR ex20ins mutations.

Read the detailed description

This study will evaluate the efficacy and safety of zipalertinib in combination with standard chemotherapy with pemetrexed and a platinum agent (either carboplatin or cisplatin) in patients with previously untreated, locally advanced or metastatic nonsquamous NSCLC harboring EGFR ex20ins mutations.

The study will be conducted in two parts:

  • Part A: Safety lead-in to determine the recommended dose of zipalertinib in combination with standard chemotherapy pemetrexed and a platinum agent (either carboplatin or cisplatin) to be studied in Part B of the study.
  • Part B: Randomized, controlled, open-label, multinational Phase 3 study to assess the efficacy and safety of zipalertinib in combination with standard chemotherapy with pemetrexed and a platinum agent (either carboplatin or cisplatin) compared to standard chemotherapy alone. Patients randomized to the chemotherapy-only treatment arm in Part B may receive treatment with zipalertinib as monotherapy after BICR-assessed progressive disease (PD) is documented (optional "crossover arm").

An independent data monitoring committee (IDMC) will be established to monitor interim safety Data.

A treatment cycle is defined as 21 days for both parts of the study.

Part A: Safety Lead-In The primary objective of Part A is to determine the recommended dose of zipalertinib administered in combination with pemetrexed and a platinum agent (either carboplatin or cisplatin) to be studied in the Phase 3 portion of this study.

Approximately 6-12 patients will receive zipalertinib administered at an initial dose of zipalertinib PO BID (Dose Level 1) in combination with pemetrexed and carboplatin or cisplatin on a 21-day cycle. Patients may continue to receive study treatment until documentation of progressive disease (PD) or until other withdrawal criteria are met, whichever comes first. Patients will be enrolled using a rolling-6 design,35 and the determination of the dose of zipalertinib to be used in Part B of the study will be informed by the incidence of dose-limiting toxicities (DLTs) observed during Cycle 1.

Part B: Phase 3 Enrollment into the Phase 3 portion of the study will begin following completion of Part A.

Approximately 260 patients will be randomized on a 1:1 basis to receive pemetrexed and a platinum agent (either carboplatin or cisplatin) with or without zipalertinib on a 21-day cycle.

Carboplatin or cisplatin will be administered for 4 cycles. Patients may continue to receive zipalertinib (experimental study arm) and pemetrexed (both study arms) until documentation of PD or until other withdrawal criteria are met, whichever comes first.

03

Conditions studied

  • Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation

Browse trials for

Keywords

  • Exon 20 insertion mutation
  • NSCLC
  • phase 3
  • Lung disease
  • Carcinoma, Non-Small-Cell Lung
  • CLN-081
  • TAS6417
  • EGFR
04

In context

Carcinoma, Non-Small-Cell Lung Reclassified

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

This study's enrollment of 285 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.

Browse Carcinoma, Non-Small-Cell Lung studies →

Lead sponsor

Taiho Oncology, Inc. is the lead sponsor of 66 studies on the registry; 9 are open to participants now.

Of its 25 completed or terminated interventional studies of FDA-regulated products, 13 (52%) have results posted.

Compared within Carcinoma, Non-Small-Cell Lung, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide written .
  2. ≥18 years of age (or meets the country's regulatory definition for legal adult age, whichever is greater).
  3. confirmed, locally advanced or nonsquamous NSCLC
  4. Has not received any prior systemic treatment for their locally advanced or metastatic nonsquamous NSCLC. Prior /neoadjuvant treatment received >6 months prior to first dose of study treatment is allowed for early-stage

    NSCLC. Prior monotherapy with an approved EGFR TKI (ie, gefitinib, erlotinib, afatinib, dacomitinib, or osimertinib) as nonstandard therapy for the treatment of locally advanced or metastatic disease is allowed if all of the following criteria are met:

    1. Treatment duration did not exceed 8 weeks;
    2. Lack of disease response was documented (radiographically) by an increase in tumor burden (a copy of the computerized tomography [CT] report showing increase in tumor burden from baseline should be submitted);
    3. Associated toxicities have resolved to baseline; and
    4. The EGFR TKI was discontinued at least 2 weeks or 4 half-lives prior to randomization, whichever is longer.

    Prior therapy with EGFR TKI agents targeting exon20ins mutations including amivantamab, mobocertinib, sunvozertinib, furmonertinib, and poziotinib is not allowed.

  5. Documented EGFR mutation status, as determined by local testing performed at a CLIA certified (US) or accredited (outside of the US) local laboratory, defined as follows:

    1. Part A: EGFR ex20ins or other uncommon single or compound EGFR mutation
    2. Part B: EGFR ex20ins mutation
  6. available for submission, with minimum quantity sufficient to evaluate EGFR mutation status and, where possible, other biomarkers. Patients with insufficient tissue (details provided in laboratory manual) may be eligible following discussion with the sponsor; a fresh biopsy will not be required.
  7. Patients with (es) who have previously received definitive local treatment and have stable central nervous system (CNS) disease (defined as being neurologically stable and off for at least 2 weeks prior to enrollment) are eligible. If brain metastases are diagnosed on screening imaging, the patient may be rescreened for eligibility after definitive treatment.

    b. Asymptomatic brain metastases ≤2 cm in size can be eligible for inclusion if, in the opinion of the Investigator, immediate definitive treatment is not indicated.

  8. At least one as determined per 1.1 for patients enrolling to Part B. Patients enrolling to Part A may be enrolled without measurable disease.
  9. (ECOG) performance status 0 or 1.
  10. Adequate organ function, as defined by the laboratory value
  11. Have a of at least 3 months as assessed by the investigator.
  12. Women of (WOCBP) must have a negative serum pregnancy test prior to administration of the first dose of study treatment. Female patients are not considered to be of childbearing potential if they are (no menses for 12 months without an alternative medical cause) or permanently sterile (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy).
  13. Both males and females of must agree to use effective during the study prior to the first dose and for 6 months after the last dose of study treatment or longer, based on local requirements.

Exclusion criteria

Exclusion -

  1. Is currently receiving an drug in a clinical trial or participating in any other type of medical research judged not to be scientifically or medically compatible with this study.
  2. Prior treatment with any of the following within the specific time frame specified:

    1. Zipalertinib (TAS6417/CLN-081) at any time.
    2. Thoracic radiotherapy ≤28 days, palliative radiation of nonthoracic disease ≤14 days, or palliative radiation of a single lesion ≤7 days prior to first dose of study treatment.
    3. Major surgery (excluding placement of vascular access) ≤28 days prior to first dose of study treatment.
    4. All prescribed medication, over-the-counter medication, vitamin preparations and other food supplements, or herbal medications that are strong or moderate inducers or inhibitors within 7 days prior to first dose.
  3. Have any unresolved toxicity of Grade ≥2 from previous anticancer treatment in the or adjuvant setting, except for Grade 2 alopecia or skin pigmentation. Patients with other chronic but stable Grade 2 toxicities may be allowed to enroll after agreement between the investigator and Sponsor.
  4. Past medical history of interstitial lung disease, treatment-related pneumonitis (any grade), or any evidence of clinically active interstitial lung disease.
  5. Impaired cardiac function or cardiac disease, including any of the following:

    1. History of congestive heart failure (CHF) Class III/IV according to the (NYHA) Functional Classification .
    2. Serious cardiac arrhythmias requiring treatment.
    3. Resting interval (QTc) >470 msec calculated using Fridericia's formula (QTcF).
  6. Unable to swallow tablets or has any disease or condition that may significantly affect gastrointestinal (GI) absorption of zipalertinib (such as inflammatory bowel disease, malabsorption syndrome, or prior GI resection).
  7. History of another primary ≤2 years prior to the date of first dose of study treatment unless at least one of the following criteria are met:

    1. Adequately treated basal or squamous cell carcinoma of the skin
    2. Cancer of the breast or cervix in situ
    3. Previously treated malignancy, if all treatment for that malignancy was completed at least 2 years prior to first dose of study treatment, and no current evidence of disease
    4. Concurrent malignancy determined to be clinically stable and not requiring tumor directed treatment
  8. Known history of , , or (HIV) that is unstable or not controlled with treatment.
  9. History of COVID-19 infection within 4 weeks prior to enrolment and/or have persistent, clinically significant pulmonary symptoms related to prior COVID-19 infection.
  10. Active bleeding disorders.
  11. Known to the ingredients in zipalertinib or any drugs similar in structure or class. To platinum-containing drugs (ie, cisplatin, carboplatin), pemetrexed, or any known of these drugs. b. toning drugs (ie, cisplatin, carboplatin) or pemetrexed according to the respective local labels.
  12. History of and spinal cord compression.
  13. Is unable or unwilling to take dexamethasone, folic acid, and/or vitamin B12 supplementation during treatment with pemetrexed.
  14. Is pregnant or lactating or planning to become pregnant
  15. The patient is, in the investigator's opinion, unable or unwilling to comply with the trial procedures.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
285 participants (actual)

Study arms

  • Experimental
    Part A (Safety Lead in)

    Part A: Safety Lead-In Approximately 6-12 patients will receive zipalertinib administered at an initial dose of zipalertinib PO BID (Dose Level 1) in combination with pemetrexed and carboplatin or cisplatin on a 21-day cycle. Patients may continue to receive study treatment until documentation of progressive disease (PD) or until other withdrawal criteria are met, whichever comes first.

    Drug: TAS6417

  • Experimental
    Part B

    Enrollment into the Phase 3 portion of the study will begin following completion of Part A. Approximately 260 patients will be randomized on a 1:1 basis to receive pemetrexed and a platinum agent (either carboplatin or cisplatin) with or without zipalertinib on a 21-day cycle. Carboplatin or cisplatin will be administered for 4 cycles. Patients may continue to receive zipalertinib (experimental study arm) and pemetrexed (both study arms) until documentation of PD or until other withdrawal criteria are met, whichever comes first.

    Drug: TAS6417

Interventions

  • oral tablets

    Also known as: Zipalertinib, CLN-081

07

What researchers measure

Primary outcomes

  1. Part A and B: The rate and severity of treatment emergent AEs

    Time frame: approximately 5 years

  2. Part A and Part B: Progression-free survival (PFS) by blinded independent central review (BICR)

    Time frame: approximately 5 years

  3. Part A: The rate and severity of DLTs according to the NCI-Common Terminology Criteria of Adverse Events (CTCAE) v5.0 during Cycle 1

    Time frame: approximately 5 years

Secondary outcomes

  1. Part A and Part B: Objective response rate (ORR)

    Time frame: approximately 5 years

  2. Part A and Part B: Disease control rate (DCR)

    Time frame: approximately 5 years

  3. Part A and Part B: Duration of response (DoR)

    Time frame: approximately 5 years

  4. Part A and Part B: Intracranial (i) Overall Response Rate (iORR)

    Time frame: approximately 5 years

  5. Part A and Part B: Intracranial duration of complete response (iDCR)

    Time frame: approximately 5 years

  6. Part A and Part B: Intracranial duration of Response (iDoR)

    Time frame: approximately 5 years

  7. Part B: Overall survival (OS)

    Time frame: approximately 5 years

  8. Pharmacokinetic (PK) parameter

    Minimum observed concentration (Cmin)

    Time frame: approximately 5 years

  9. European Quality of Life 5 Dimensions, 3 Level Version (EQ-5D-3L)

    The EQ-5D-3L descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results into a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. This scale is numbered from 0 to 100. The higher the score the better the outcome

    Time frame: approximately 5 years

  10. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30

    The EORTC QLQ-C30 is a "core questionnaire" which incorporates a range of physical, emotional and social health developed to assess the quality of life of cancer patients. This scale is numbered from 30 to 130. The higher the score equates to better functioning.

    Time frame: approximately 5 years

  11. Non-small Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ )

    The NSCLC- SAQ was developed to incorporate the patient's perspective into evaluation of clinical benefit in advanced non-small cell lung cancer trials.. Qualitative evidence supports 7 items covering 5 symptom concepts with the total score measuring overall severity of the following NSCLC symptoms: cough, pain, dyspnea, fatigue, and appetite. Lower scores indicate lower symptom severity.

    Time frame: approximately 5 years

Other outcomes

  1. Pharmacokinetic (PK) parameter

    Minimum Plasma Concentration \[Cmin\]

    Time frame: approximately 5 years

  2. Pharmacokinetic (PK) parameter

    Maximum Plasma Concentration \[Cmax\]

    Time frame: approximately 5 years

  3. Pharmacokinetic (PK) parameter

    Area Under Curve \[AUC\]

    Time frame: approximately 5 years

  4. EGFR mutation status

    local central tests results

    Time frame: approximately 5 years

08

Study locations

110 sites

Showing the first 100 of 110 sites across 22 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Heymach JV, Yu HA, Besse B, Cheng Y, Tan DS, Wei L, Wacheck V, Nishio M. REZILIENT3: randomized phase III study of first-line zipalertinib plus chemotherapy in patients with EGFR exon 20 insertion-mutated NSCLC. Future Oncol. 2025 Feb;21(5):549-556. doi: 10.1080/14796694.2025.2457294. Epub 2025 Feb 16. PubMed 39957151 ↗
10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for May 2027, 41 months after the start.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 41 months is close to that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2023
First posted
Aug 3, 2023
StartActual
Dec 18, 2023
Primary completionEst.
May 27, 2027
CompletionEst.
May 27, 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
30 sites added, 50 sites removed; no longer in Bulgaria
Show 30 added (8 Turkey (Türkiye), 7 Spain, 6 Italy, 3 South Korea, 2 Japan, 2 Mexico, 1 Israel, 1 Romania)
  • Assuta Hospital - Ramat HaHayal · Tel Aviv, Israel
  • Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele · Milan, Italy
  • Azienda Ospedaliero - Universitaria di Modena · Modena, Italy
  • Fondazione IRCCS Policlinico San Matteo · Pavia, Italy
  • Azienda Unità Sanitaria Locale della Romagna · Ravenna, Italy
  • IRCCS Istituto Nazionale Tumori Regina Elena · Roma, Italy
  • Azienda Ospedaliera Universitaria Integrata Verona · Verona, Italy
  • Osaka City General Hospital · Osaka, Japan
  • Osaka Prefectural Hospital Organization - Osaka International Cancer Institute · Osaka, Japan
  • Investigacion Medica Galerias · Aguascalientes, Mexico
  • FAICIC Clínical Research · Veracruz, Mexico
  • Clinica SIGMedical · Suceava, Romania
  • Inha University Hospital · Incheon, South Korea
  • Korea University Anam Hospital · Seoul, South Korea
  • Korea University Guro Hospital · Seoul, South Korea
  • Clínica Mi Tres Torres · Barcelona, Spain
  • Hospital Quirónsalud Barcelona · Barcelona, Spain
  • Hospital Clinic de Barcelona · Barcelona, Spain
  • Hospital Universitario Fundación Jiménez Díaz · Madrid, Spain
  • Hospital Universitario 12 de Octubre · Madrid, Spain
  • Hospital Universitario La Paz · Madrid, Spain
  • Hospital Regional Universitario de Málaga - Hospital General · Málaga, Spain
  • Medical Park Seyhan Hastanesi · Adana, Turkey (Türkiye)
  • Hacettepe Üniversitesi Kanser Enstitüsü · Ankara, Turkey (Türkiye)
  • Memorial Ankara Hastanesi · Ankara, Turkey (Türkiye)
  • T.C. Saglik Bakanligi Ankara Bilkent Sehi?r Hastanesi? · Çankaya, Turkey (Türkiye)
  • Trakya Üniversitesi Sa?l?k Ara?t?rma ve Uygulama Merkezi · Edirne, Turkey (Türkiye)
  • Ankara Il Saglik Mudurlugu SBU Gulhane Egitim Ve Arastirma Hastanesi · Etlik, Turkey (Türkiye)
  • Bagcilar Medipol Mega Universite Hastanesi · Istanbul, Turkey (Türkiye)
  • T.C. Saglik Bakanligi - Istanbul Il Saglik Mudurlugu - Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi · Istanbul, Turkey (Türkiye)
Show 50 removed
  • Comprehensive Cancer Centers of Nevada - Horizon Ridge Henderson · Henderson, United States
  • Multi-profile Hospital for Active Treatment Uni Hospital · Panagyurishte, Bulgaria
  • University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna-ISUL · Sofia, Bulgaria
  • Instituto Oncológico Fundación Arturo López Pérez · Providencia, Chile
  • Hôpital Haut-Lévêque · Pessac, France
  • Centre Hospitalier Le Mans · Le Mans, France
  • Gustave Roussy · Villejuif, France
  • Asklepios Klinik Altona · Hamburg, Germany
  • Metropolitan General · Piraeus, Greece
  • University General Hospital of Patras · Patra, Greece
  • Metropolitan Hospital · Piraeus, Greece
  • BioClinic Thessaloniki · Thessaloniki, Greece
  • University General Hospital of Larissa · Larissa, Greece
  • Hadassah University Hospital Ein Kerem · Jerusalem, Israel
  • Assuta Hospital - Ramat HaHayal · Tel Aviv, Israel
  • Tel Aviv Sourasky Medical Center · Tel Aviv, Israel
  • Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele · Milan, Italy
  • Azienda Ospedaliero - Universitaria di Modena · Modena, Italy
  • Fondazione IRCCS Policlinico San Matteo · Pavia, Italy
  • Azienda Unità Sanitaria Locale della Romagna · Ravenna, Italy
  • IRCCS Istituto Nazionale Tumori Regina Elena · Roma, Italy
  • Azienda Ospedaliera Universitaria Integrata Verona · Verona, Italy
  • Kanagawa Cardiovascular and Respiratory Center · Yokohama, Japan
  • Osaka City General Hospital · Osaka, Japan
  • Osaka Prefectural Hospital Organization - Osaka International Cancer Institute · Osaka, Japan
  • Investigacion Medica Galerias · Aguascalientes, Mexico
  • FAICIC Clínical Research · Veracruz, Mexico
  • Medisprof · Cluj-Napoca, Romania
  • Clinica SIGMedical · Suceava, Romania
  • Oncocenter - Oncologie Clinica · Timișoara, Romania
  • …and 20 more on the registry record
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    30 sites added, 50 sites removed; no longer in Bulgaria
    Show 30 added (8 Turkey (Türkiye), 7 Spain, 6 Italy, 3 South Korea, 2 Japan, 2 Mexico, 1 Israel, 1 Romania)
    • Assuta Hospital - Ramat HaHayal · Tel Aviv, Israel
    • Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele · Milan, Italy
    • Azienda Ospedaliero - Universitaria di Modena · Modena, Italy
    • Fondazione IRCCS Policlinico San Matteo · Pavia, Italy
    • Azienda Unità Sanitaria Locale della Romagna · Ravenna, Italy
    • IRCCS Istituto Nazionale Tumori Regina Elena · Roma, Italy
    • Azienda Ospedaliera Universitaria Integrata Verona · Verona, Italy
    • Osaka City General Hospital · Osaka, Japan
    • Osaka Prefectural Hospital Organization - Osaka International Cancer Institute · Osaka, Japan
    • Investigacion Medica Galerias · Aguascalientes, Mexico
    • FAICIC Clínical Research · Veracruz, Mexico
    • Clinica SIGMedical · Suceava, Romania
    • Inha University Hospital · Incheon, South Korea
    • Korea University Anam Hospital · Seoul, South Korea
    • Korea University Guro Hospital · Seoul, South Korea
    • Clínica Mi Tres Torres · Barcelona, Spain
    • Hospital Quirónsalud Barcelona · Barcelona, Spain
    • Hospital Clinic de Barcelona · Barcelona, Spain
    • Hospital Universitario Fundación Jiménez Díaz · Madrid, Spain
    • Hospital Universitario 12 de Octubre · Madrid, Spain
    • Hospital Universitario La Paz · Madrid, Spain
    • Hospital Regional Universitario de Málaga - Hospital General · Málaga, Spain
    • Medical Park Seyhan Hastanesi · Adana, Turkey (Türkiye)
    • Hacettepe Üniversitesi Kanser Enstitüsü · Ankara, Turkey (Türkiye)
    • Memorial Ankara Hastanesi · Ankara, Turkey (Türkiye)
    • T.C. Saglik Bakanligi Ankara Bilkent Sehi?r Hastanesi? · Çankaya, Turkey (Türkiye)
    • Trakya Üniversitesi Sa?l?k Ara?t?rma ve Uygulama Merkezi · Edirne, Turkey (Türkiye)
    • Ankara Il Saglik Mudurlugu SBU Gulhane Egitim Ve Arastirma Hastanesi · Etlik, Turkey (Türkiye)
    • Bagcilar Medipol Mega Universite Hastanesi · Istanbul, Turkey (Türkiye)
    • T.C. Saglik Bakanligi - Istanbul Il Saglik Mudurlugu - Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi · Istanbul, Turkey (Türkiye)
    Show 50 removed
    • Comprehensive Cancer Centers of Nevada - Horizon Ridge Henderson · Henderson, United States
    • Multi-profile Hospital for Active Treatment Uni Hospital · Panagyurishte, Bulgaria
    • University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna-ISUL · Sofia, Bulgaria
    • Instituto Oncológico Fundación Arturo López Pérez · Providencia, Chile
    • Hôpital Haut-Lévêque · Pessac, France
    • Centre Hospitalier Le Mans · Le Mans, France
    • Gustave Roussy · Villejuif, France
    • Asklepios Klinik Altona · Hamburg, Germany
    • Metropolitan General · Piraeus, Greece
    • University General Hospital of Patras · Patra, Greece
    • Metropolitan Hospital · Piraeus, Greece
    • BioClinic Thessaloniki · Thessaloniki, Greece
    • University General Hospital of Larissa · Larissa, Greece
    • Hadassah University Hospital Ein Kerem · Jerusalem, Israel
    • Assuta Hospital - Ramat HaHayal · Tel Aviv, Israel
    • Tel Aviv Sourasky Medical Center · Tel Aviv, Israel
    • Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele · Milan, Italy
    • Azienda Ospedaliero - Universitaria di Modena · Modena, Italy
    • Fondazione IRCCS Policlinico San Matteo · Pavia, Italy
    • Azienda Unità Sanitaria Locale della Romagna · Ravenna, Italy
    • IRCCS Istituto Nazionale Tumori Regina Elena · Roma, Italy
    • Azienda Ospedaliera Universitaria Integrata Verona · Verona, Italy
    • Kanagawa Cardiovascular and Respiratory Center · Yokohama, Japan
    • Osaka City General Hospital · Osaka, Japan
    • Osaka Prefectural Hospital Organization - Osaka International Cancer Institute · Osaka, Japan
    • Investigacion Medica Galerias · Aguascalientes, Mexico
    • FAICIC Clínical Research · Veracruz, Mexico
    • Medisprof · Cluj-Napoca, Romania
    • Clinica SIGMedical · Suceava, Romania
    • Oncocenter - Oncologie Clinica · Timișoara, Romania
    • …and 20 more on the registry record
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05973773
Responsible party
Sponsor
First posted
Aug 3, 2023
Start date
Dec 18, 2023
Primary completion
May 27, 2027 (estimated)
Completion
May 27, 2027 (estimated)
Last update
Nov 3, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zipalertinib

Start the discussion